Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Stienen, S (Author) Other; Ferreira, JP (Author) FMUP; Bar, C (Author) Other; Thum, T (Author) Other; Barros, A (Author) FMUP; Pitt, B (Author) Other; Girerd, N (Author) Other; Rossignol, P (Author) Other; Zannad, F (Author) Other

Journal

Title: International Journal of Cardiology

Vol. 332

Pages: 35-37

ISSN: 0167-5273

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 6 Citations

Other information

Authenticus ID: P-00T-J8T

DOI: 10.1016/j.ijcard.2021.02.088

Abstract (EN): Background: After myocardial infarction (MI) complicated by heart failure (HF), eplerenone reduced serum con-centrations of amino-terminal propeptide of type III collagen (PIIINP) and carboxy-terminal propeptide of type I collagen (PICP). Determining a subgroup who are more prone to decrease their collagen content and to respond better to the antifibrotic effects of mineralocorticoid receptor antagonists (MRA) may be relevant for a personal-ized treatment approach. Whether circulating microRNAs may identify a subgroup that have experienced a more pronounced antifibrotic effect of eplerenone as measured by a PICP and PIIINP decrease is unclear. Methods: A set of circulating microRNAs linked to cardiac fibrosis (mir-1, mir-21, mir-29a, mir-29b, mir-101, mir -122, mir-133a) were measured at baseline in 198 patients in the biomarker substudy of Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Associations between baseline microRNA levels and changes in both PIIINP and PICP from baseline to month 9 were studied using multivariable analysis of covariance, adjusting for age, sex, history of hypertension and diabetes mellitus, prescription of ACE-inhibitors or angiotensin receptor blockers, baseline PIIINP or PICP, and eplerenone treatment. Furthermore, a treatment-by-microRNA interaction was studied. Results: From the selected microRNAs, only mir-133a was associated with a PICP decrease (ss-6.43, 95%CI-12.71 to & minus;0.15,p = 0.045). None of the microRNAs was associated with a PIIINP change. The microRNAs did not predict an effect of eplerenone on PICP and PIIINP changes. Conclusion: Although serum mir-133a was associated with PICP change, none of the microRNAs previously linked to cardiac fibrosis predicted an antifibrotic response to eplerenone. Further study is needed to identify other suit-able targets for a personalized treatment approach.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 3